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Studying ciliopathies, like the Bardet-Biedl syn-
drome (BBS), allow the identification of signaling
pathways potentially involved in common diseases,
sharing phenotypic features like obesity or type 2
diabetes. Given the close association between
obesity and insulin resistance, obese BBS patients
would be expected to be insulin resistant. Surpris-
ingly, we found that a majority of obese BBS patients
retained normal glucose tolerance and insulin sensi-
tivity. Patient’s adipose tissue biopsies revealed
upregulation of adipogenic genes and decrease of
inflammatory mediators. In vitro studies on human
primary mesenchymal stem cells (MSCs) showed
that BBS12 inactivation facilitated adipogenesis,
increased insulin sensitivity, and glucose utilization.
We generated a Bbs12/ mouse model to assess
the impact of Bbs12 inactivation on adipocyte
biology. Despite increased obesity, glucose toler-
ance was increased with specific enhanced insulin
sensitivity in the fat. This correlated with an active
recruitment of MSCs resulting in adipose tissue
hyperplasia and decreased in inflammation.
INTRODUCTION
Better understanding of the molecular mechanisms underlying
obesity-associated type 2 diabetes mellitus (T2DM) is a high
research priority in view of the global obesity pandemic. Many
therapeutic approaches have been developed to help reduce
obesity and T2DM, including peroxisome proliferator-activated
receptors (PPAR)-g agonists, cannabinoid receptor antagonists,
and serotonin uptake inhibitors (Berger et al., 1996; Kast-Woel-
bern et al., 2004; Spiegelman, 1998), but unfortunately many ofCell Methese treatments including rosiglitazone, rimonabant, and sibutr-
amine have been subsequently withdrawn from use due to side
effects (Kohlroser et al., 2000; Scheen, 2001). There is conse-
quently a major unmet need for new therapies for the rapidly
growing population of patients with obesity and T2DM. Rare
genetic disorders have emerged as valuable models for discov-
ering new pieces of the jigsaw on the origins of obesity and
insulin resistance leading to T2DM (Nachury et al., 2007). Cilio-
pathies are a group of inherited monogenic syndromes due to
a defect in the primary cilium, an ubiquitously distributed organ-
elle implicated in the detection, transmission, and interpretation
of various types of intracellular and extracellular signals (Hilde-
brandt et al., 2011; Mok et al., 2010; Satir et al., 2010; Sen Gupta
et al., 2009; Cardenas-Rodriguez and Badano, 2009; Girard and
Petrovsky, 2011; Mockel et al., 2011; Novarino et al., 2011).
Interestingly, several of the ciliopathies including the Bardet
Biedl syndrome (BBS) and Alstrom syndrome are associated
with morbid obesity and diabetes. BBS is genetically heteroge-
neous ciliopathy, with 17 BBS genes identified so far, but with
a cardinal clinical trait of all BBS types being severe obesity
(Ge´ne´reux et al., 2011; Sheffield, 2010; Zaghloul and Katsanis,
2009). BBS-induced obesity has previously been proposed to
be due to the incapacity of the hypothalamus to respond to leptin
(Rahmouni et al., 2008a), the appetite-controlling hormone
synthesized and secreted by adipose tissue. This effect was
ascribed to a failure of the transport of the leptin receptor to
the primary cilium (Seo et al., 2009) of hypothalamic neurons re-
sulting in hyperphagia, as observed in various BBS knockout
mouse models and described in human case reports (Berbari
et al., 2008). We previously demonstrated that the differentiating
preadipocyte is transiently ciliated (Marion et al., 2009), associ-
ated with a peak expression of the different BBS proteins (Forti
et al., 2007). In vitro BBS inactivation during adipocyte differen-
tiation resulted in enhanced adipogenesis through repression of
antiadipogenic signaling pathways including the Wnt cascade,
combined with activation of proadipogenic pathways through
increased expression of PPARg, highlighting the role of BBStabolism 16, 363–377, September 5, 2012 ª2012 Elsevier Inc. 363
Figure 1. Human BBS Adipose Tissue Phenotype
(A) Glucose tolerance test in BBS obese patients (BMI >30 kg/m2).
(B) Insulin response curve to glucose administration in the corresponding BBS patients.
(C) Pictures of AdipoRed-stained subcutaneous adipocytes from the corresponding BBS patients.
(D) Adipocyte cell size in corresponding subcutaneous adipose tissue (R200 cells per patient).
(E) Circulating Leptin concentration in the corresponding BBS patients.
(F) Relative mRNA levels in the subcutaneous adipose tissue of the corresponding BBS patients.
(G) Adipogenic gene-expression levels in subcutaneous WAT in the subcutaneous adipose tissue of the corresponding BBS patients.
(H) Inflammatory-related gene-expression levels in the subcutaneous adipose tissue of the corresponding BBS patients.
Values are expressed as mean ± SEM; n = 6–8 patients in (A)–(E); n = 4 in (F), (G), and (H); *p < 0.05. See also Table S2.
Cell Metabolism
Bardet Biedl Syndrome and Obesity Phenotypeproteins in the regulation of adipogenesis. Interestingly, a recent
metabolic study carried on 50 young (average age 15 years)
BBS patients and 100 obese BMI-matched controls made the
surprising finding that obese BBS patients had, despite greater
visceral adiposity, better glucose tolerance and lower glycosy-
lated hemoglobin than obese non-BBS controls (Feuillan et al.,
2011), suggesting that BBS gene mutations have a positive
effect on glucose regulation despite inducing visceral adiposity.
Given the tight link between visceral adiposity and insulin resis-
tance in all other forms of obesity, we wished to understand
how in the presence of obesity and hyperleptinaemia BBS
patients are able to avoid insulin resistance and maintain nor-
moglycemia with the hope that this could lead to therapeutic
strategies to reverse obesity-associated T2DM. In particular,
we wished to test the hypothesis that the BBS proteins play
a key role in regulation of adipocyte differentiation, and interrup-
tion of BBS signaling disinhibits adipocyte generation leading to
increased adipocyte insulin sensitivity with a lack of low-grade364 Cell Metabolism 16, 363–377, September 5, 2012 ª2012 Elsevieinflammation, which thereby provides a glucose sink in adipose
tissue.
RESULTS
Phenotype of Human BBS Fat Tissue
Obesity is a cardinal clinical feature of BBS (Beales, 2005). To
characterize this phenotype, we performed oral glucose toler-
ance tests (oGTT) and plasma insulin and leptin profiles on a
group of obese adult subjects (n = 16, mean age 27 years and
mean BMI >30 kg/m2) with identified BBS mutations (Table S1
for list of mutated patients). The subjects with BBS had a mean
fasting blood glucose pre-oGTT of 4.85mmol/L, which increased
to a mean of 6.71 mmol/L at 120 min after glucose ingestion.
Thus, according to the 1999 WHO criteria for interpretation of
oGTT results, obese BBS subjects were not glucose intolerant
(Figure 1A). The plasma insulin profile during the oGTT also re-
mainedwithin the normal range (Figure 1B). Subsequent analysisr Inc.
Figure 2. Bbs12 Depletion Represses Antiadipogenic Pathways Hence Favoring Adipogenesis
(A) Primary cilium (red) detected in hMSCs at day 4 of adipogenic differentiation with surrounding pericentriolar material (green).
(B) Centrioles (arrows) detected at the base of the primary cilium at day 4 of adipogenic differentiation.
(C) Relative mRNA levels of BBS12 during adipogenic differentiation of hMSCs.
(D) Relative mRNA levels of BBS12 in hMSCs at D4 of adipogenic differentiation.
(E) Immunodetection of BBS12 with corresponding b-tubulin immunodetection as loading control.
(F) Relative mRNA levels of adipogenic regulatory genes at D4 of adipogenic differentiation.
Values are expressed as mean ± SEM; n = 4 in (C), (D), (E), and (F); *p < 0.05 for differentiation versus proliferation levels in (C) and CTRLsiRNA versus
BBS12siRNA in (D) and (E). See also Table S1 and Figure S1.
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BBS patients and controls with comparable BMI (>30 kg/m2)
demonstrated similar adipocyte cell size with a mean diameter
of 100 mm (Figures 1C and 1D). Characteristic hyperleptinemia
was also found in the BBS patients (Figure 1E) Gene-expression
analysis of adipose tissue from subjects with BBS (Figure 1F)
demonstrated increased expression of key genes involved in
insulin signaling pathways including the insulin receptor (INSR),
insulin receptor substrate 1 (IRS1), and glucose transporter 4
(SLC2A4). Similarly, the expression of PPARg and downstream
adipogenic PPARg response genes, FAS, ACC, SCD2, and
SREBP1c were all increased in BBS adipose tissue (Figure 1G).
Obesity gives rise to a state of chronic, low-grade inflammation
associated with infiltration of macrophages (Greenberg and
Obin, 2006; Shoelson et al., 2006a). Anti-inflammatory and
antidiabetic Adiponectin, endothelial nitric oxide synthase
(eNOS), and Interleukin10 gene expression were found upregu-
lated in the BBS adipose tissue. This correlated with lower levels
of marcrophage marker CD68 and proinflammatory mediators
such as inducible nitric oxide (iNOS) and tumor necrosis factor
alpha (TNFa) in the BBS obese patients’ adipose tissue high-
lighting an absence of inflammation.
Inactivation of BBS12 in hMSCs Favors Adipogenic
Differentiation
To understand the basis for this upregulated insulin signaling
pathway gene-expression profile in human BBS adipose tissue,Cell Mewe studied adipocyte differentiation using human mesenchymal
stem cells (hMSCs), adipocyte precursors, originating from the
bone marrow (Cristancho and Lazar, 2011; Slagman et al.,
2011) among which ciliated cells could be detected (Figures
S1A and S1B). On day 4 of adipogenic differentiation, transient
primary cilia were observed on the differentiating hMSCs (Fig-
ure 2A), with the characteristic feature of centrioles at their
basal body (arrows; Figure 2B, right picture). Concomitant to
this transient ciliated status, BBS12 mRNA expression levels
peaked (Figure 2C) (as did the transcript levels of other interact-
ing chaperone BBS proteins; BBS10 and BBS6 (Seo et al., 2010)
(Figure S1C). siRNA-mediated knockdown of any of the three
interacting chaperone BBS proteins resulted in a significant
decrease in the number of ciliated cells indicating these
BBS proteins are required during adipogenic differentiation of
hMSCs (Figures 2D, 2E, S1D, and S1E).
To assess the involvement of BBS12 expression for adipo-
genic differentiation of hMSC, we performed siRNA-mediated
knock down of BBS12 on hMSC and then measured the ex-
pression of regulatory adipogenic genes at differentiation day 4
(corresponding to 5 days post-siRNA treatment) (Figure 2D).
Significantly reduced expression levels of Hedgehog (GLI2,
GLI3), Wnt (Laudes, 2011; Taipaleenma¨ki et al., 2011)
(Wnt10B), and Notch (NOTCH1) signaling pathways as well as
the transcription factor CHOP (Batchvarova et al., 1995) were
observed in BBS12-depleted hMSCs (Figure 2E), indicating
repression of antiadipogenic pathways. At the same time,tabolism 16, 363–377, September 5, 2012 ª2012 Elsevier Inc. 365
Figure 3. Increase Glucose Absorption Capacity in BBS12-Deprived Adipocytes
(A) Immunodetection IR and GLUT4 on cell lysates from 1-week-old mature human adipocytes.
(B–D) 3D representation of mature adipocytes showing the effect of Ins. on actin mesh (red) and GLUT4 localization (green).
(E) Glut4 membrane content upon Ins. stimulation.
(F) 2-NBDG absorption with ±Ins. stimulation.
(G) Fluorescent quantification of intracellular 2-NBDG in adipocytes ±Ins. stimulation.
(H) AdipoRed staining of intracellular triglycerides (TG) in green and plasma membrane stained with Image-iT (red).
(I) Fluorescent quantification of the corresponding intracellular TG content.
(J) Adipogenic gene expression levels in 2-week-old mature adipocytes.
(K) Leptin concentration in 4 days conditioned adipocyte culture medium from 3-week-old primary mature adipocytes
Values are expressed as mean ± SEM, n = 8 in (G) and (I); n = 4 in (K) and (L); *p < 0.05 for CTRL siRNA versus BBS12 siRNA. See also Table S3 and Figure S2.
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PPARG,WNT5B, and DKK1 were significantly increased, hence
favoring hMSC adipogenesis. Collectively, these results show
that BBS12 inactivation favors adipogenesis in hMSCs by re-
pressing antiadipogenic signaling cascades.
BBS12 Inactivation Increases Glucose Absorption
by Mature Human Adipocytes
PPARg expression improves insulin sensitivity and increases
glucose uptake in mature adipocytes (Chiarelli and Di Marzio,
2008; Choi et al., 2011) by regulating genes involved in glucose
metabolism. Following BBS12 inactivation in hMSC, we ob-
served significantly increased expression of the insulin receptor
(IR) and GLUT4 protein levels (Figures 3A, S2A, and S2B). We
next tested whether BBS12 inactivation impacted on IR and
GLUT4 cellular dynamics in response to insulin stimulation. In366 Cell Metabolism 16, 363–377, September 5, 2012 ª2012 Elseviethe absence of insulin, the IR and GLUT4 were located at the
cell periphery and inside an intracellular compartment, respec-
tively (de Foresta et al., 2011) (Figure S2C). GLUT4 was localized
below an intact actin mesh (Figures 3B and S2D, –Ins.). In
response to insulin treatment for 30 min, again irrespective of
BS12 expression, the actin mesh was disorganized and GLUT4
was targeted to the cell membrane (Figures 3C and S2D;
30 min Ins.). GLUT4 recycling was also unaffected in absence
of BBS12 as 2 hr after the removal of insulin, the actin network
was restored and GLUT4 was recycled back inside the intra-
cellular space (Figures 3D and S2D; 30 min Ins.; 2 hr –Ins.).
However, the increased GLUT4 expression in BBS12-depleted
adipocytes was associated with an increased GLUT4 plasma
membrane content after insulin stimulation (Figures 3E and
S2E). Importantly, the increased IR and GLUT4 expression
levels and membrane targeting upon insulin stimulation inr Inc.
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absorption capacity as measured by 1.5 fold higher absorption
of the fluorescent glucose analog, 2-NBDG by BBS12-depleted
adipocytes (Figures 3F and 3G).
BBS12Depletion in HumanAdipocytes Increases Insulin
Sensitivity, Enhances Glucose Absorption, and
Increases Intracellular Triglyceride Content
Having found an increased glucose absorption in BBS12-
depleted adipocytes, we measured intracellular TG levels in
2-week-old mature adipocytes (Figure 3H) and found sig-
nificantly higher TG content in BBS12-depleted adipocytes
(Figure 3I), a feature previously described in adipocytes derived
from BBS patients’ dermal fibroblasts (Marion et al., 2009). To
explain the increased TG content, we performed a comparative
analysis of genes involved in fat metabolism in BBS12-depleted
adipocytes. Expression levels of FAS, ACC, SCD, and SREBF1
were upregulated in BBS12-depleted adipocytes (Figure 3J). In
addition, leptin concentration in 4 day adipocyte-conditioned
medium was higher for the BBS12-depleted 3-week-old mature
adipocytes (Figure 3K).
The Bbs12 Knockout Mouse (Bbs12–/–) Reproduces BBS
Cardinal Clinical Features including Obesity
To unravel the pathophysiological implications underlying the
above findings on human BBS-depleted adipocytes, we gener-
ated a Bbs12 knockout mouse (Bbs12/) model using the
approach depicted in Figures S3A and S3B. No Bbs12 expres-
sion could be measured in Bbs12/ tissues as exemplified in
the adipose tissues and the kidneys (Figure 4A). Bbs12/
mice, although smaller at birth (Figure 4B), reached the weight
of the WT control littermates at 8 week-old and finally became
obese later in life. Food intake in mice of same weight (8 weeks
of age) was significantly higher in Bbs12/ mice (Figure 4C),
whereas nocturnal energy expenditure was similar between the
two groups (Figure S3C). At 12 weeks of age, the Bbs12/
mice were clearly obese (Figure 4D) and presented retinal
degeneration defined by a thinning of the outer nuclear layer
(ONL) and the loss of the outer segment (OS) (Figure 4E).
Bbs12/ mice did not exhibit detectable structural renal
abnormality like cystogenesis at 16 weeks of age (Figure S3D),
unlike some other previously described BBS mouse models.
Hyperleptinemia, a common trait in other BBS mouse models
and human patients (Feuillan et al., 2011; Imhoff et al., 2011;
Rahmouni et al., 2008a), was also present in Bbs12/ mice
(Figure 4F). Associated with the obese phenotype, Bbs12/
epididymal fat deposits were 1.5 times bigger than wild-type
(WT) littermates (Figure 4G) and the lipogenic proteins FAS and
AceCS1 were increased in Bbs12/ adipose tissue (Figures
4H and S3E).
Obese Bbs12–/– Mice Present Increased Insulin
Sensitivity
To better understand the impact of BBS12-induced ciliary
dysfunction on the fat biology, we measured fasting glucose
and insulin levels in obese Bbs12/ mice (40 g body weight)
and WT littermates (30 g body weight) and found no significant
differences (Figures 5A and 5B), thereby mimicking our findings.
Interestingly, obese Bbs12/ mice had lower peak glucoseCell Melevels in the GTT than WT mice (Figure 5C). The corresponding
plasma insulin in the first hour after glucose administration simi-
larly showed no significant difference plasma insulin levels in
the Bbs12/ mice compared to the WT (Figure 5D). Consistent
with absence of BBS12 conferring enhanced insulin sensitivity,
the insulin tolerance test (ITT) that demonstrated an enhanced
hypoglycemic response to injected insulin in the obese
Bbs12/mice (Figure 5E). Overall, these data show that despite
their obesity Bbs12/ mice have enhanced rather than dimin-
ished insulin sensitivity.
BBS12-Deficient Adipocytes Have Enhanced Insulin
Sensitivity and Glucose Absorption
The enhanced hypoglycemic response to insulin in Bbs12/
mice could result from increased insulin sensitivity of other non-
adipose insulin-responsive tissues, such as liver or muscle. To
assess whether the effect of BBS12 inactivation on insulin sensi-
tivity was tissue specific, we injected insulin (5U/kg body weight)
into fasted mice and 30 min later harvested the liver, muscle,
and visceral adipose tissue. Insulin-mediated phosphorylation
of AKT on serine 473 (p-AKT) was significantly increased in
Bbs12/ adipose tissues but not in liver or muscle, suggesting
that the increased insulin sensitivity of Bbs12/ mice was
predominantly localized to adipose tissue (Figures 5F–5H). To
confirm this finding, we measured p-AKT levels in isolated
primary adipocytes in response to insulin stimulation and found
BBS12-depleted adipocytes had double the amount p-AKT
(Figures 5I and S4). Increased p-AKT correlated with a 3-fold
increase in 2-NBDG uptake determined after fixation and subse-
quent 3D volumetric measurements of the intracellular 2-NBDG
content (Figures 5J and 5K), a finding confirmed by determining
the ratio of total fluorescence over total protein quantity (Fig-
ure 5L). This demonstrated that Bbs12/ adipocytes are the
primary site of increased insulin sensitivity and enhanced glu-
cose absorption.
Bbs12-Induced Ciliary Defect Favors MSCs’ Adipogenic
Program and thereby Contributes to Adipose Tissue
Hyperplasia and Increased Cell Autonomous Insulin
Sensitivity
To explore the respective roles of hyperphagia and increased
calorie load versus enhanced adipogenic differentiation on the
development of obesity in BBS, we compared four different
groups of male mice, namely WT mice, Bbs12/ mice, hyper-
phagic Ob/Ob mice, and a fourth group of pharmacologically
induced adipogenic mice designed as TZD mice. Obesity linked
to compulsive feeding behavior in Ob/Ob mice has previously
been associated with hypertrophic adipose tissue (Calderan
et al., 2006). The TZD mice were WT mice with pharmacologi-
cally induced adipogenesis by treatment with Troglitazone and
Ciglitazone, two thiazolidinedione (TZD) ligands for PPARg.
Examination of visceral adipocytes revealed that Bbs12/
adipocytes were heterogeneous in size with a large proportion
of small cells together with larger ones (Figure 6A). On average,
these Bbs12/ adipocytes were significantly larger than WT
adipocytes (Figure 6B). Ob/Ob adipocytes were homogenous
and hypertrophic in size compared to WT and Bbs12/ adipo-
cytes whereas TZD-treated adipocytes were heterogeneous in
size and significantly smaller than the other groups. Expressiontabolism 16, 363–377, September 5, 2012 ª2012 Elsevier Inc. 367
Figure 4. Bbs12–/– Male Mouse Phenotype
(A) Relative mRNA expression levels of Bbs12 in target tissues of Bbs12/ and control WT littermates.
(B) Growth curve of Bbs12/ and control WT littermates.
(C) Food intake of 8-week-old Bbs12/ and control WT littermates.
(D) Photograph of Bbs12/ and control WT littermate.
(E) Retinal degeneration inBbs12/mouse compared to controlWT littermate. OS: outer segment, CC: connecting cilium; ONL: outer nuclear layer (rhodopsin in
green, acetylated a-tubulin in red, and nuclei in blue).
(F) Circulating leptin concentrations in Bbs12/ and control WT littermates.
(G) Visceral fat mass of Bbs12/ and control WT littermates.
(H) Adipogenic protein levels in visceral fat.
Values are expressed as mean ± SEM, n = 6–8 in (A), (B), (F), and (G); n = 4 in (C). *p < 0.05 for Bbs12/ versus WT. See also Table S4 and Figure S3.
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whose expression directly correlates with adipocyte size (Le
Lay et al., 2001), were increased in Ob/Ob hypertrophic adipo-
cytes and decreased in both Bbs12/ and TZD adipocytes
relative to WT controls (Figure 6C). Interestingly, cell count
showed that, on average, there were more cells per unit square
are in the Bbs12/ adipose tissue compare to WT ones (Fig-368 Cell Metabolism 16, 363–377, September 5, 2012 ª2012 Elsevieure 6D).This suggests that hyperplasia plays an important role
in adipose tissue expansion in Bbs12/ mice thereby
accounting for the greater adiposity of Bbs12/ mice and
human BBS patients (Feuillan et al., 2011). IR and GLUT4 protein
content in the cellular extracts of adipose tissues from the
different mouse groups showed a significant increase of IR and
GLUT4 in both Bbs12/ and TZD adipocytes compared to WTr Inc.
Figure 5. Improved Glucose Metabolism and Insulin Sensitivity of the Adipose Tissue in 12-Week-Old Male Bbs12–/– Mice
(A) Fasting blood glucose levels in Bbs12/ and control WT littermates.
(B) Fasting blood insulin levels in Bbs12/ and control WT littermates.
(C) Glucose tolerance tests and corresponding area under the curves.
(D) Insulin response curve and corresponding area under the curves.
(E) Insulin tolerance tests and corresponding area under the curves.
(F) Insulin stimulated phospho-AKT (Ser473) in adipose tissue in Bbs12/ and control WT littermates.
(G) Insulin stimulated phospho-AKT (Ser473) in liver in Bbs12/ and control WT littermates.
(H) Insulin stimulated phospho-AKT (Ser473) in muscle in Bbs12/ and control WT littermates.
(I) Insulin stimulated phospho-AKT (Ser473) in primary adipocytes derived from Bbs12/ and control WT littermates adipose tissues.
(J) 3D image of insulin stimulated 2-NBDG fluorescent glucose analog (green) in primary adipocytes. Plasma membrane in red (Image-iT) and nucleus in
blue (DAPI).
(K) 3D volumetric determination of intracellular 2-NBDG content in primary adipocytes.
(L) Ratio of fluorescent levels of intracellular 2-NBDG content/total protein quantity.
Values are expressed as mean ± SEM; n = 6–8 in (A), (B), (C), (D), and (E). n = 60 per mouse with 3 mice per genotype in K. n = 6 wells per condition in L *p < 0.05
for Bbs12/ versus WT. All mice were fed ad libitum on defined 45% fat chow. See also Figure S4.
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Bardet Biedl Syndrome and Obesity Phenotypecontrols (Figures 6E and S5), corroborating the initial in vitro
results described in Figure 3A.
To clarify the basis of the heterogeneity of cell size of adipo-
cytes in the Bbs12/ mice, we compared the femoral bone
marrows (BM) from the four different mouse groups (Figure 6F).
A small number of mature adipocytes (arrows; Figure 6F) were
found inside the BM of Bbs12/ and TZD mice but none in
the WT. On the other hand, the BM of the Ob/Ob was almost
completely replaced with mature adipocytes. These findings
were confirmed by the finding of increased expression levels of
adipocyte fatty acid-binding protein (Fabp4) (Figure 6G),
a marker for mature adipocytes (Balzar et al., 2011), in the BM
of Ob/Ob, Bbs12/, and TZD mice compared to WT. Owing
to the crosstalk taking place in MSCs between adipogenic and
osteoblastic differentiation (Muruganandan et al., 2009), any
condition that activates adipogenesis such as the Bbs12/,
Ob/Ob, and the TZD (Gimble et al., 1996) phenotypes, inevitably
impacts the osteoblastic differentiation process. We therefore
determined the expression levels of three osteoblastic genes
(Ap3d1, Runx2, and Osteocalcin) and found a reduction of all
three genes in the BM of Ob/Ob, Bbs12/, and TZD mice
compared to WT, albeit nonsignificant in the Bbs12/ group
(Figure 6H).
Remarkably, in the TZD and theOb/ObBM, Bbs12 expression
levels were significantly increased (Figure 6I), validating previous
in vitro results (Marion et al., 2009) that during adipogenic differ-
entiation, Bbs12 expression is increased. We also wanted to
know whether the enhanced adipogenic program exhibited by
the MSCs was intrinsically related to the in-cell BBS12-induced
defect or whether there could be another factor favoring the
differentiation. To address this question, mouse MSCs (mMSCs)
from WT and Bbs12/ mice were isolated, cultured, and char-
acterized (Figure S6), before adipogenesis was triggered (Fig-
ure 6J). Bbs12/ mMSCs reproduced the same phenotype as
the Bbs12-RNAi treated hMSCs; namely, they demonstrated
an enhanced adipogenic program leading to higher intracellular
triglyceride contents and increased Fabp4 expression (Fig-
ure 6K), consistent with enhanced BBS12 expression during
adipogenesis acting as an adipogenic brake, which is released
when BBS is absent or inhibited.
A model encompassing the effect of the BBS-induced impact
on adipogenic differentiation is depicted in Figure 6L. In the
WT condition, MSC differentiation toward adipocytes is tightly
regulated by theWnt and Shh antiadipogenic signaling pathwaysFigure 6. Bbs12 Inactivation Favors Adipogenesis in the Bone Marrow
(A) AdipoRed stained adipocytes from 40 g male mice with corresponding genot
(B) Adipocyte cell count from 40 g male mice with corresponding genotype and
(C) Adipocyte cell size measurements from 40 g male mice with corresponding g
(D) Relative mRNA expression levels of Srebf2 in corresponding adipose tissue.
(E) IR and GLUT4 protein levels in corresponding visceral adipose tissues.
(F) Toluidin blue staining of femoral BM (arrows indicate adipocytes).
(G) Relative mRNA expression levels of Fabp4 in corresponding BM extracts.
(H) Relative mRNA expression levels of osteogenic genes in corresponding BM e
(I) Relative mRNA expression of Bbs12 in the BM.
(J) AdipoRed-stained adipocytes derived ex vivo from primary mouse MSCs (mM
(K) Relative mRNA expression levels of Fabp4 in adipocytes derived mMSCs.
(L) Schematic representation of the BBS impact on MSC recruitment from the bo
Values are expressed as mean ± SEM. In (B) and (C), n = 200 per mouse with 3 m
*p < 0.05 for tested group versus WT. See also Figures S5 and S6.
Cell Mein which the primary cilium plays a key functional role (Fontaine
et al., 2008; Suh et al., 2006). The equilibrium between pro-
and antiadipogenic signals results in MSC differentiation into
homogenously sized adipocytes in WT animals. Conversely,
primary cilium dysfunction through BBS12 inactivation disables
these antiadipogenic brakes, thereby facilitating the recruitment
of MSCs toward adipogenic differentiation. The end result of
this enhanced recruitment of MSCs into adipocytes in BBS is
an increased, heterogeneously sized population of adipocytes
with high IR and GLUT4 expression—a consistent finding
reproduced in human patients with BBS, human, and mouse
MSC cultures and Bbs12/ mice as seen in this study.
Adipocyte Function in Bbs12–/– Mice and Inflammation
The rate of free fatty acid (FFA) mobilization from the adipose
tissue to the portal vein correlates with insulin resistance and is
associated with inflammatory response in macrophages. Circu-
lating FFA was lower in Bbs12/ (Figure 7A), and upon insulin
injection, FFA suppression was significantly higher in the
Bbs12/ (Figure 7B). These results confirmed a higher adipose
tissue insulin sensitivity of the Bbs12/ adipose tissue. Adipo-
kine measurements showed increased levels of Adiponectin
(Figure 7C) and decreased levels of Resistin (Figure 7D), high-
lighting an adipokine profile favoring insulin sensitivity in the
Bbs12/ mice. Inflammation is a major cause of insulin resis-
tance in the adipose tissue associated with accumulation of
activated macrophages in the adipose tissue, and their quanti-
ties correlate with measures of insulin resistance (Greenberg
and Obin, 2006; Shoelson et al., 2006b). Recruitment and proin-
flammatory activation of adipose tissue macrophages are
required for the development of diabetes with obesity. Recruit-
ment is mainly governed by the level of the monocyte chemoat-
tractant protein-1 (MCP-1) (Kanda et al., 2006), and circulating
MCP-1 levels were similar in Bbs12/ and WT controls when
normalized with body weight (Figure 7E). Macrophages are
plastic cells with two distinct flavors (Gordon and Taylor, 2005;
Mantovani et al., 2004), either the proinflammatory M1 flavor
secreting high levels of proinflammatory mediators such as
TNFa and IL-6 (Harkins et al., 2004; Xu et al., 2003) or the M2
flavor. The later represent a group of macrophages with low
proinflammatory cytokine producers and instead generate high
levels of antiinflammatory cytokines like IL10 (Gordon, 2003).
Interestingly, circulating IL-6 levels were not different between
the tested groups whereas TNFa levels were significantly lowerCausing Adipose Tissue Hyperplasia
ype and treatment.
treatment.
enotype and treatment.
xtracts.
SCs).
ne marrow to the adipose tissue.
ice per group. n = 4 in (G), (H), (I), and (K). *p < 0.05 for tested group versus WT.
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mice are systemically not inflamed.
We next investigated the inflammatory gene-expression
profile in the adipose tissue. For that, we compared gene-
expression profile in peri-renal white adipose tissue from 40 g
male Bbs12/ mice and WT age-controls mice (Figure 7H).
Interestingly, a selection of anti-inflammatory genes (eNOS,
Adiponectin, IL13 [Gordon, 2003], IL10, and Arginase1 [Arg1]
[Bronte and Zanovello, 2005]) were significantly upregulated.
Alternatively, select proinflammatory genes (Cd68, Mcp-1,
iNos, Tnfa,Cox1, Serpine, and Resistin) were significantly down-
regulated, while other immunorelated genes were similar. In
aggregate, these findings highlight the absence of low-grade
inflammation in the obese Bbs12/ adipose tissue.
The observed protective phenotype of BBS was next tested
in diet-induced obesity challenged mice. Male Bbs12/ mice
at 6-month-old became massively obese (on average 54 g),
whereas the WT controls remained at 40 g (Figure 7I and 7J).
Blood glucose levels in overnight fasted animals were signifi-
cantly higher in WT mice compared to the Bbs12/ (Figure 7K).
Concurrently, all measured proinflammatory markers (MCP-1,
IL-6, and TNF-a) were higher in the WT group compared to the
Bbs12/ (Figures 7L–7N). Concomitant with the proinflamma-
tory cytokine profile, there was a significant increase in macro-
phage infiltration in the adipose tissue of the WT compared to
the Bbs12/ (Figure 7O). These results demonstrate that the
primary cilium regulates the maturation and function of the
adipose tissue. Moreover, a disruption in this ciliary control is
able to favor adiposity while preventing deleterious inflammatory
response.
DISCUSSION
Obesity is a cardinal clinical feature of BBS, and yet, unlike other
obesity associated ciliopathies such as Alstrom Syndrome,
based on our observations and those of others (Feuillan et al.,
2011), surprisingly T2DM is not per se a common feature of
BBS. Indeed we show here that Bbs12/ mice despite obesity
have significantly greater glucose tolerance and insulin sensi-
tivity than lean WT control littermates. Examination of the effects
of inactivation of the ciliary protein BBS12 in human boneFigure 7. Decreased Adipose Tissue Inflammation in Bbs12–/– Mice
(A) Blood FFA levels in 12-week-old mice.
(B) Insulin-stimulated percentage of FFA suppression in 12-week-old mice.
(C) Circulating Adiponectin in WT and Bbs12/ mice in 12-week-old mice.
(D) Circulating Resistin in WT and Bbs12/ mice in 12-week-old mice.
(E) Circulating TNF-a correlated to body weight in 12-week-old mice.
(F) Circulating IL-6 correlated to body weight in 12-week-old mice.
(G) Circulating MCP-1 correlated to body weight in 12-week-old mice.
(H) Table showing a group of selected genes, function, fold change in Bbs12/
gene expression decreased; in black: gene expression similar.
(I) Photograph of 6-month-old mice fed with 45% fat and 35%carbohydrate.
(J) Body weight of male mice weight at 6 months.
(K) Blood glucose level in 6-month-old mice.
(L) Circulating MCP-1 correlated to body weight in 6-month-old mice.
(M) Circulating IL-6 correlated to body weight in 6-month-old mice.
(N) Circulating TNF-a correlated to body weight in 6-month-old mice.
(O) 3D images of adipose tissue blood vessels immunostained for macrophages
Values are expressed as mean ± SEM; n = 6–8 in (A)–(G) and in (J)–(N); n = 4 in (
Cell Memarrow MSC showed that absence of BBS12 favored pro-
gramming of MSC toward adipocyte differentiation through
simultaneous inhibition of antiadipogenic, and activation of
proadipogenic, pathways. This results in increased glucose
uptake and triglyceride synthesis capacity together with low
levels of local inflammatory response in the adipose tissue.
Although not a defining trait of the BBS, diabetes has histori-
cally been considered as a secondary feature of this ciliopathy.
It is indeed true that throughout literature, it has been described
that aminority of BBS patients developed type 2 diabetes (Webb
et al., 2009), including our own previous published data (Imhoff
et al., 2011). It is therefore surprising that BBS inactivation can
actually be protective against diabetes. Several reasons can
explain this apparent discrepancy observed in the human condi-
tions. One reason is that, historically BBS like the other related
ciliopathies was diagnosed based on the association of charac-
teristic clinical features. But with the advent of high-throughput
sequencing and the discovery of the continuously increasing
number of identified of genes involved in these ciliopathies
(with the new BBS17 recently identified in our lab [Marion
et al., 2012]), we are now more able to make clearer distinctions
between the BBS and the other related ciliopathies. For instance,
we were recently able to illustrate the pitfall of purely based clin-
ical categorization of the BBS where patients who were clinically
suspected of having BBS were actually mutated in the Alms1
gene, the other ciliopathy mainly characterized by obesity and
diabetes (Aliferis et al., 2012). Second, a so far underestimated
reason that explains that a minority of BBS patients may develop
diabetes is what is nowadays considered as phenotypic varia-
tion. As described in a Scientific Perspective entitled Mendelian
Puzzles (Chakravarti and Kapoor, 2012), not all individuals with
an identical mutation are equally affected. Indeed, the idea that
a single mutation in one gene causes the clinical phenotype is
evolving as human genetics keep evolving from a focus of single
genes into a more genomic view. This means that all sorts of in-
teracting genetic variants may give rise to different degree of
dysfunction. This applied to the BBS might explain the diabetes
phenotype in this minority of BBS patients, a feature that
warrants more research.
Interestingly, the fact that chaperone BBS proteins are only
maximally expressed during MSC differentiation suggests thatadipose tissue compared to WT. In green: genes expression increased; in red:
(CD68 in red) and nuclei (DAPI).
H). *p < 0.05 for tested group versus WT.
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and BBS proteins may not be involved in mature adipocyte func-
tion. This is supported by the fact that inactivation of BBS
proteins in mature adipocytes resulted in no detectable effects
(Figure S7). Most of the BBS proteins share the same expression
profile (Forti et al., 2007; Marion et al., 2009) and form an interac-
tion complex (Jin et al., 2010; Nachury et al., 2007), suggesting
they should have a common role in MSC differentiation. BBS
proteins are not the only ciliary proteins impacting on adipogen-
esis if inactivated. Partial in vivo inactivation of Polycystin 1
(Pkd1), another ciliary protein, activated adipogenesis in mouse
bone marrow (Qiu et al., 2010). Surprisingly, this proadipogenic
effect of Pkd1 inactivation was reversed by concomitant partial
decrease of another ciliary protein, Kif3a. These data provide
evidence of the coexistence of two distinct groups of ciliary
proteins, one whose action is antiadipogenic such that their
inactivation is proadipogenic, like Bbs12 and Pkd1, and one
whose action is proadipogenic such that their inactivation is
antiadipogenic, like Kif3a. These findings indicate that ciliary
proteins likely act as gatekeepers, controlling the progression
of cells through adipocyte differentiation. This process of
controlling adipocyte recruitment towards the adipose tissue is
most probably the origin of the lack of inflammatory response
observed in the Bbs12/ mice and most probably in the
patients, too. Inflammatory response is triggered by a poor
access of oxygen and food supply to the mature adipocytes in
overdeveloped tissue. This eventually leads to cellular death
thereby activating the inflammatory cascade. Inactivation of
BBS proteins activates the recruitment of precursor cells to the
adipose tissue, thereby creating a continuous refurnishing of
small adipocytes in the adipose tissue. These new cells prevent
the already existing mature adipocytes to absorb excessive
glucose to become hypertrophic and thereby prevent low-grade
inflammation, the condition responsible for insulin resistance of
the adipose tissue.
Remarkably, preadipocytes derived from patients with T2DM
have been described as less prone to adipogenic differentiation
(van Tienen et al., 2011), suggesting that resistance of preadipo-
cytes to adipogenic differentiation may be an important contrib-
utor to insulin resistance. The opposite effect is observed in
patients with BBSwho have increased adipogenic differentiation
with consequent enhanced insulin sensitivity and increased
adipocyte glucose uptake capacity. This explains why even
morbidly obese BBS patients have a disproportionately low
frequency and severity of T2DM. Although the adipose tissue
is clearly more insulin sensitive and has a higher glucose absorp-
tive capacity, we cannot totally exclude some other parameters
contributing to the overall phenotype. A hallmark of T2DM is
adipose tissue insulin resistance, with this being the target of
the TZD family of antidiabetic drugs that act to lower plasma
glucose levels at least in part by increasing the number of
small-sized adipocytes (MacKellar et al., 2009). The phenotype
resulting from the BBS-associated ciliary defect in adipose
tissue mimics the effect of TZD, namely adipose tissue hyper-
plasia associated with increased insulin sensitivity.
Our data shows that Bbs12/ adipose tissue is heteroge-
neous with a mixture of both hyperplasia and hypertrophy,
suggesting the obesity in BBS is due to a combination of hypo-
thalamic hyperphagia plus increased recruitment of adipocyte374 Cell Metabolism 16, 363–377, September 5, 2012 ª2012 Elsevieprogenitors. High plasma leptin levels in BBS patients (and
Bbs12/ mice) does not correlate with patient adiposity (Feuil-
lan et al., 2011), suggesting intrinsic leptin resistance in BBS.
This likely reflects the failure of the leptin receptor to be targeted
to the primary cilium resulting in incapacity of leptin-responsive
neurons to respond to leptin (Seo et al., 2009). This implies
that in BBS, the downstream targets of the Leptin receptor fail
to be activated, including Signal transducer and activator of
transcription (Stat)-3 and Phosphoinositide 3-kinase (PI3K)
signaling in POMC neurons. In support, impairment of central
leptin-mediated PI3K signaling induced hepatic steatosis and
excessive TG accumulation in the liver that was independent of
hyperphagia and obesity (Warne et al., 2011). In addition,
adipose tissue dysfunction has been linked to nonalcoholic
hepatic steatosis (Duval et al., 2010). To identify if the BBS
phenotype was prosteatotic, we determined the hepatic TG
content and found a 3-fold increase in the Bbs12/ compared
to a 14-fold increase in Ob/Ob mice and no change in TZD
mice (Figures S7C and S7D). The fact that BBS livers were less
steatotic compared to Ob/Ob livers suggests partial residual
leptin signaling in the hypothalamus—a finding previously
described in Bbs2, 4, and 6 knockout mice where Pomc expres-
sion levels were, although decreased, still expressed (Rahmouni
et al., 2008b).
While these observations might nevertheless suggest a
decrease in leptin in BBS by way of feedback, extremely high
leptinaemia was observed in both humans and mice with BBS.
This could be explained by the fact that adipocytes secrete leptin
in response to insulin and, most importantly, proportionately to
the amount of glucose absorbed (Mueller et al., 1998). With
maintained insulin levels and increased glucose absorption
capacity, we showed that BBS adipocytes in vitro secreted
more leptin, a finding previously observed in adipocytes derived
from dermal fibroblasts of our patients with BBS (Marion et al.,
2009). The fact that leptin secretion was reduced in the presence
of cytochalasin B, an inhibitor of glucose absorption (Figure S7E),
confirms the direct link between increased glucose absorption
and increased adipocyte leptin secretion in BBS. In aggregate,
this suggests that the BBS phenotype is a combination of adipo-
cyte-mediated hyperleptinaemia with partial leptin resistance in
the hypothalamus.
An intriguing finding was the normal fasting plasma insulin
levels in the Bbs12/ mice despite the increased in vivo,
ex vivo, and in vitro insulin sensitivity of BBS12-deficient adipo-
cytes. The expected effect of increased cell autonomous insulin
sensitivity would be a reduction in fasting insulin levels. As
increased pancreatic islet size was reported as a key feature of
obese diabetic models such asOb/Ob (Yokoi, 2010) or Alstrom’s
Foz/foz mice (Arsov et al., 2006), we examined the pancreas of
Bbs12/ mice but found no increase in islet size (mean surface
area 70000 mm2; data not shown). These findings seem to
indicate that the insulin level might be influenced by another
tissue that is also impacted in the BBS—an area that warrants
further investigations. Also, insulin regulates glucose homeo-
stasis primarily through suppression of hepatic glucose pro-
duction and stimulation of peripheral glucose uptake, primarily
in the muscle and to a lesser extent in the adipose tissue
(DeFronzo et al., 1985; Weyer et al., 1999). Therefore, even in
obesity, the contribution of the adipose tissue to glucose uptaker Inc.
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BBS condition, even though the adipose tissue is bigger and
more sensitive to insulin and has a higher capacity for glucose
absorption, it cannot by itself regulate the overall glucose
homeostasis. A probable parameter of the adipose tissue
impacting systemic glucose levels in the BBS patients and the
BBS models could be the low level of low-grade inflammation
of the adipose tissue. How and to what extent the absence of
inflammatory stimuli in the BBS contributes in preventing insulin
resistance will require further investigations.
In conclusion, although human ciliopathies are extremely
rare conditions, they provide opportunity for unique insights
into key cellular pathways including those involved in adipocyte
differentiation, obesity, and insulin resistance. In particular, the
disconnect between obesity and T2DM in BBS suggests that
modulation of primary cilia regulation of adipogenic pathways,
most probably by regulating the enzymatic activity of some
BBS proteins such as BBS3, may be a potential target for
reversal of obesity-associated insulin resistance and T2DM.
EXPERIMENTAL PROCEDURES
Human Tests and Samples
The subcutaneous adipose tissue biopsies, glucose tolerance tests, and
insulin response curves were performed on BBS patients (see Farha et al.
[2011] and Marion et al. [2011] for age, sex, pedigree, and phenotype)
studied as part of a clinical research protocol in the Protocole Hospitalier
de Recherche Clinique National Program (PHRC) undertaken at the Univer-
sity Hospital of Strasbourg, France. No studied patient had renal dialysis
or renal transplantation. Patients provided written informed consent under
the authority of the local ethics committee. The adipose tissue sample at
a depth of 1 cm beneath the skin was obtained after a biopsy procedure
(available on request) performed by a plastic surgeon on the abdominal fat
tissue.
Animal Treatment
They were individually caged and fed ad libitum. The defined 45% fat chow
(Research Diets D06011802) was used also to feed the KO mice and WT
controls as the Ob/Ob mice were fed with this diet at Jackson Labs until
they reached the 40 g threshold. They were then euthanized by decapitation
for analysis. For the TZD treatment, a combination of both ciglitizone and
troglitazone at a concentration of 250 mg/kg body weight/day each (to prevent
steatotic side effects in the hepatocytes) was added to the drinking water
and was given to the mice sharing the same genetic mixed background as
the Bbs12/. These mice were fed on the same commercial high fat diet ad
libitum for a 1 month period initiated at 12 weeks postnatal. To challenge the
mice for obesity and diabetes, we fed a group of male mice with a diabetic
inducing diet (45 kcal% fat and 35 kcal% carbohydrate) (Research Diets
D12451) for 6 months and then carried the analysis.
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Supplemental Information includes seven figures, five tables, Supplemental
Experimental Procedures, and Supplemental References and can be found
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